DrugPatentWatch Database Preview
Exeltis Usa Inc Company Profile
» See Plans and Pricing
What is the competitive landscape for EXELTIS USA INC, and when can generic versions of EXELTIS USA INC drugs launch?
EXELTIS USA INC has three approved drugs.
There are four US patents protecting EXELTIS USA INC drugs.
There are forty patent family members on EXELTIS USA INC drugs in twenty-seven countries and thirty-six supplementary protection certificates in fourteen countries.
Summary for Exeltis Usa Inc
| International Patents: | 40 |
| US Patents: | 4 |
| Tradenames: | 3 |
| Ingredients: | 3 |
| NDAs: | 3 |
Drugs and US Patents for Exeltis Usa Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exeltis Usa Inc | SLYND | drospirenone | TABLET;ORAL | 211367-001 | May 23, 2019 | RX | Yes | Yes | 10,603,281 | Start Trial | Start Trial | ||||
| Exeltis Usa Inc | TYBLUME | ethinyl estradiol; levonorgestrel | TABLET;ORAL | 209405-001 | Mar 30, 2020 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Exeltis Usa Inc | ESTRASORB | estradiol hemihydrate | EMULSION;TOPICAL | 021371-001 | Oct 9, 2003 | DISCN | Yes | No | Start Trial | Start Trial | |||||
| Exeltis Usa Inc | SLYND | drospirenone | TABLET;ORAL | 211367-001 | May 23, 2019 | RX | Yes | Yes | 10,849,857 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Exeltis Usa Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Exeltis Usa Inc | ESTRASORB | estradiol hemihydrate | EMULSION;TOPICAL | 021371-001 | Oct 9, 2003 | 5,629,021 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Exeltis Usa Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Guatemala | 201200336 | Start Trial |
| Hungary | S2000016 | Start Trial |
| Mexico | 2019004393 | Start Trial |
| Lithuania | 2588114 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Exeltis Usa Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1453521 | 39/2015 | Austria | Start Trial | PRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211 |
| 1453521 | C201630040 | Spain | Start Trial | PRODUCT NAME: ETINILESTRADIOL Y MEZCLA DE LEVONORGESTREL Y ETINILESTRADIOL; NATIONAL AUTHORISATION NUMBER: 80340; DATE OF AUTHORISATION: 20160122; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 17/0017/15-S; DATE OF FIRST AUTHORISATION IN EEA: 20150211 |
| 0770388 | 9/2009 | Austria | Start Trial | PRODUCT NAME: KOMBINATION AUS ESTRADIOLVALERAT UND DIENOGEST; NAT. REGISTRATION NO/DATE: 1-28003 20090203; FIRST REGISTRATION: BE BE 327792 20081103 |
| 1380301 | 2009C/007 | Belgium | Start Trial | PRODUCT NAME: DROSPIRENONE-ETHINYLESTRADIOL; AUTHORISATION NUMBER AND DATE: BE321386 20080811 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
